Zealand Pharma
311.50 DKK
+1.96 %
Less than 1K followers
ZEAL
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+1.96 %
+4.53 %
-22.01 %
-33.21 %
-34.71 %
-35.65 %
+40.19 %
+58.04 %
+291.82 %
Zealand Pharma operates in biotechnology. Special focus is found in the development of drugs for the treatment of diabetes and various intestinal diseases. The company has a varied product portfolio with separate brands that are sold on a global level. The largest operations are in the Nordic market. Zealand Pharma was founded in 1997 and is headquartered in Søborg, Denmark.
Read moreMarket cap
22.28B DKK
Turnover
69.9M DKK
Revenue
9.21B
EBIT %
75.52 %
P/E
3.4
Dividend yield-%
-
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
7/5
2026
Interim report Q1'26
26/5
2026
Extraordinary general meeting '26
13/8
2026
Interim report Q2'26
All
Press releases
ShowingAll content types
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools